Nowak A - Search Results

1

European expert consensus statement on therapeutic goals in Fabry disease.

Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, Germain DP, Hughes DA, Jovanovic A, Kantola I, Linhart A, Mignani R, Monserrat L, Namdar M, Nowak A, Oliveira JP, Ortiz A, Pieroni M, Spada M, Tylki-Szymańska A, Tøndel C, Viana-Baptista M, Weidemann F, Hilz MJ. Wanner C, et al. Among authors: nowak a. Mol Genet Metab. 2018 Jul;124(3):189-203. doi: 10.1016/j.ymgme.2018.06.004. Epub 2018 Jun 12. Mol Genet Metab. 2018. PMID: 30017653 Review.

2

The value of ECG parameters as markers of treatment response in Fabry cardiomyopathy.

Schmied C, Nowak A, Gruner C, Olinger E, Debaix H, Brauchlin A, Frank M, Reidt S, Monney P, Barbey F, Shah D, Namdar M. Schmied C, et al. Among authors: nowak a. Heart. 2016 Aug 15;102(16):1309-14. doi: 10.1136/heartjnl-2015-308897. Epub 2016 Apr 7. Heart. 2016. PMID: 27056970

3

Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes.

Nowak A, Mechtler TP, Desnick RJ, Kasper DC. Nowak A, et al. Mol Genet Metab. 2017 Jan-Feb;120(1-2):57-61. doi: 10.1016/j.ymgme.2016.10.006. Epub 2016 Oct 19. Mol Genet Metab. 2017. PMID: 27773586 Free article.

4

General Anesthesia and Fabry Disease: A Case Report.

Krüger S, Nowak A, Müller TC. Krüger S, et al. Among authors: nowak a. A A Case Rep. 2017 May 15;8(10):247-249. doi: 10.1213/XAA.0000000000000479. A A Case Rep. 2017. PMID: 28079663 Free article.

5

Disease Progression Modeling to Evaluate the Effects of Enzyme Replacement Therapy on Kidney Function in Adult Patients with the Classic Phenotype of Fabry Disease.

Nowak A, Koch G, Huynh-Do U, Siegenthaler M, Marti HP, Pfister M. Nowak A, et al. Kidney Blood Press Res. 2017;42(1):1-15. doi: 10.1159/000464312. Epub 2017 Feb 28. Kidney Blood Press Res. 2017. PMID: 28253518 Free article.

6

Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease.

Nowak A, Mechtler T, Kasper DC, Desnick RJ. Nowak A, et al. Mol Genet Metab. 2017 Aug;121(4):320-324. doi: 10.1016/j.ymgme.2017.06.006. Epub 2017 Jun 17. Mol Genet Metab. 2017. PMID: 28663131

7

Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease.

Lenders M, Oder D, Nowak A, Canaan-Kühl S, Arash-Kaps L, Drechsler C, Schmitz B, Nordbeck P, Hennermann JB, Kampmann C, Reuter S, Brand SM, Wanner C, Brand E. Lenders M, et al. Among authors: nowak a. J Intern Med. 2017 Sep;282(3):241-253. doi: 10.1111/joim.12647. Epub 2017 Jul 26. J Intern Med. 2017. PMID: 28682471 Free article.

8

Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease.

Nowak A, Mechtler TP, Hornemann T, Gawinecka J, Theswet E, Hilz MJ, Kasper DC. Nowak A, et al. Mol Genet Metab. 2018 Feb;123(2):148-153. doi: 10.1016/j.ymgme.2017.07.002. Epub 2017 Jul 5. Mol Genet Metab. 2018. PMID: 28728877

9

Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up.

Siegenthaler M, Huynh-Do U, Krayenbuehl P, Pollock E, Widmer U, Debaix H, Olinger E, Frank M, Namdar M, Ruschitzka F, Nowak A. Siegenthaler M, et al. Among authors: nowak a. Int J Cardiol. 2017 Dec 15;249:261-267. doi: 10.1016/j.ijcard.2017.09.027. Epub 2017 Sep 19. Int J Cardiol. 2017. PMID: 28964554 Free article.

10

Reply: Impact of Cardio-Renal Syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up.

Nowak A, Siegenthaler M, Namdar M, Ruschitzka F. Nowak A, et al. Int J Cardiol. 2018 May 1;258:206. doi: 10.1016/j.ijcard.2018.01.084. Int J Cardiol. 2018. PMID: 29544933 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,544 results

Search Page